Premium Subscribers: Complete your KYC to Avoid
Service Suspension. Login Here.

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLAND PHARMA Gains 7%; BSE HEALTHCARE Index Down 1.1%
Thu, 29 Jan 10:30

GLAND PHARMA Gains 7%; BSE HEALTHCARE Index Down 1.1%Image source: StarLineArts/www.istockphoto.com

GLAND PHARMA share price has zoomed 7% and is presently trading at Rs 1,801.1.

Meanwhile, the BSE HEALTHCARE index is at 40,798.9 (down 1.1%).

Among the top gainers in the BSE HEALTHCARE index today are COHANCE LIFESCIENCES (up 1.4%) and IPCA Labs (up 0.3%).

Abbott India (down 2.8%) and Dr. Reddys (down 2.5%) are among the top losers today.

Over the last one year, GLAND PHARMA has moved up from Rs 1,440.6 to Rs 1,801.1, registering a gain of Rs 360.5 (up 25.0%).

On the other hand, the BSE HEALTHCARE index has moved down from 41,053.3 to 40,798.9, registering a loss of 0.6% during the last 12 months.

The top losers among the BSE HEALTHCARE index stocks during this same period were COHANCE LIFESCIENCES (down 60.7%), SYNGENE INTERNATIONAL (down 38.4%) and POLY MEDICURE (down 38.0%).

Live Now: The Small Cap Proxy Players Briefing

What About the Benchmark Indices?

The BSE Sensex is at 81,867.9 (down 0.6%).

The top losers among the BSE Sensex today are Asian Paints (down 2.8%) and Maruti Suzuki (down 2.8%). The most traded stocks in the BSE Sensex are Tata Steel and Eternal Ltd.

In the meantime, NSE Nifty is at 25,210.9 (down 0.5%). Maruti Suzuki and Asian Paints are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 75,366.2 to 81,867.9, registering a gain of 6,501.7 points (up 8.6%).

GLAND PHARMA Financial Update...

GLAND PHARMA net profit grew 27.7% YoY to Rs 2,615 million for the quarter ended December 2025, compared to a profit of Rs 2,047 million a year ago. Net sales rose 22.5% to Rs 16,954 million during the period as against Rs 13,841 million in October-December 2024.

For the year ended March 2025, GLAND PHARMA reported 9.6% decrease in net profit to Rs 6,985 million compared to net profit of Rs 7,725 million during FY24. Revenue of the company fell 0.9% to Rs 56,165 million during FY25.

The current Price to earnings ratio of GLAND PHARMA, based on rolling 12 month earnings, stands at 35.0.

Archives


Equitymaster requests your view! Post a comment on "GLAND PHARMA Gains 7%; BSE HEALTHCARE Index Down 1.1%". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Quantum Information Services Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

  • Registered Name:

    Quantum Information Services Private Limited

  • Registered Office Address:

    103, Regent Chambers, Nariman Point, Mumbai 400021

  • CIN:

    U65990MH1989PTC054667

  • Website:

    www.equitymaster.com

  • Compliance Officer & Grievance Officer:

    Ms. Sonal Ramachandran

    | Telephone No.: +91-22-61434003 | Email: compliance@equitymaster.com

SEBI Registered Research Analyst Details:

SEBI Registration No.: INH000021128 | Type of Registration: Non-Individual | Validity: Perpetual | BSE Enlistment No: 6769

Principal Officer: Tanushree Banerjee | Telephone No.:+91-22-61434055 | Email: po.ra@equitymaster.com

SEBI Registered Investment Adviser Details:

SEBI Registration No.: INA000000680 | Type of Registration: Non-Individual | Validity: Perpetual | BSE Enlistment No: 1488

Principal Officer: Vivek Chaurasia | Telephone No.:+91-22-61434055 | Email: po.ria@equitymaster.com

SEBI Office Details:

SEBI Bhavan BKC
Address: Plot No.C4-A, 'G' Block Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra
Telephone No.: +91-22-26449000 / 40459000 | Fax: +91-22-26449019-22 / 40459019-22 | Email: sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575
SCORES: https://www.scores.gov.in/ | SMARTODR: https://smartodr.in/login

Association of Mutual Funds of India (AMFI) Registered Details:

AMFI Registered Mutual Fund Distributor
AMFI Registration Number : ARN - 1022
Date of Initial Registration : 28 / JAN / 2008
Current Validity of ARN upto : 28 / JAN / 2028

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, enlistment with BSE as IA and RA, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing any content from this website whether wholly or in part, for any purpose without the permission of Quantum Information Services Private Limited is strictly prohibited and shall be deemed to be copyright infringement.

Quantum Information Services Private Limited (QIS) is a SEBI registered Research Analyst (bearing registration no INH000021128) and Investment Adviser(Reg. No: INA000000680). Consequent upon the merger of Equitymaster Research Private Limited into QIS, effective October 30, 2025 QIS owns and operates brand 'Equitymaster' and website www.equitymaster.com. This does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities and QIS including its employees, personnel, directors, associates will not be liable for any losses (direct or indirect) incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. All content and information is provided on an 'As Is' basis by QIS. Information herein is believed to be reliable but QIS does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. The services rendered by QIS are on a best effort basis. QIS does not assure or guarantee the user any minimum or fixed returns. The securities quoted, if any are for illustration only and are not recommendatory. Use of this information is at the user's own risk. The user must make his own investment decisions based on his specific investment objective and financial position and using such independent advisors as he believes necessary. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject QIS or its affiliates to any registration or licensing requirement.

The performance data quoted represents past performance and does not guarantee future results. As a condition to accessing QIS's content and website, you agree to our Terms and Conditions of Use, available here.